Takeda ends development of late-stage diabetes drug

"The company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam do not outweigh the potential risks,” Takeda (TKPHF) says, ending development of its late-stage GPR40 agonist TAK-875.

The drug was tied to liver damage.

The company had hoped the treatment would help offset revenue lost to generic Actos, the diabetes drug which at one time accounted for more than a quarter of Takeda's top-line.

Shares fell 5%+ in Tokyo on the news.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs